

Substitute for form 1449A/PTO

ATTORNEY'S NO.  
032775-047APPLICATION NO.  
09/847,355INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT

Donald Morris, et al.

FILING DATE

May 3, 2001

GROUP

1636

9

TECH CENTER

1600/2900

JUL 31 2001  
U.S. PATENT & TRADEMARK OFFICE

RECEIVED

FILE COPY

2001

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
DL	6,136,307		Lee, et al.	10-24-00

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
DL	WO 94/18992		WO PCT	09-01-94		
DL	WO 94/25627		WO PCT	11-10-1994		
DL	WO 99/08692		WO PCT	02-25-1999		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DL	Bar-Eli, N., et al., "preferential cytotoxic effect of Newcastle disease virus on lymphoma cells", <i>J. Cancer Res. Clin. Oncol.</i> 122: 409-415 (1996).
DL	Bensinger, W.I., "Should we purge?", <i>Bone Marrow Transplant.</i> 21:113-115 (1998).
DL	Bischöff JR. et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor", <i>Science</i> 274(5286):373-6-(1996).
DL	Blagoslelonny, M.V., et al., "in vitro Evaluation of a p53-Expressing Adenovirus as an Anti-Cancer Drug", <i>Int. J. Cancer</i> 67(3):386-392 (1996).
DL	Bos, J.L., "Ras Oncogenes in Human Cancer: A Review", <i>Canc. Res.</i> 49(17): 4682-4689 (1989).
DL	Chang et al., <i>PNAS</i> 89:4825-4829 (1992).
DL	Chang, H.W. et al., <i>Virology</i> 194:537-547 (1993).
DL	Chang et al., <i>J. Virol.</i> 69:6605-6608 (1995).
DL	Coffey, M.C., et al., "Reovirus Therapy of Tumors with Activated Ras Pathway", <i>Science</i> 282:1332-1334 (1998).
DL	Duggan, P.R., et al., "Predictive factors for long-term engraftment of autologous blood stem cells", <i>Bone Marrow Transplantation</i> 26(12): 1299-1304 (2000).
DL	Fueyo, J., et al., "A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect in Vivo", <i>Oncogene</i> 19(1):2-12 (2000).
DL	Gao, J., B. Tombal and J.T. Isaacs, "Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts", <i>Prostate</i> 39(1): 67-70 (1999).
DL	Haig, D.M., et al., <i>Immunology</i> 93(3):335-340 (1998).
DL	He, B., et al., <i>Proc. Nat. Acad. Sci.</i> 94: 843-848 (1997).
DL	Kawagishi-Kobayashi, M., et al., <i>Mol. Cell. Biology</i> 17:4146-4158 (1997).
DL	Nemunaitis, J., <i>Invest. New Drugs</i> 17:375-386 (1999).
DL	Nielsen LL., et al., "P53 Tumor Suppressor Gene Therapy for Cancer", <i>Cancer Gene Ther.</i> 5(1):52-63 (1998).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

David Lamberton

8/15/02

(05/01)

Substitute for form 1449A/PTO

ATTORNEY'S DO NO.  
032775-047APPLICATION NO.  
09/847,355APPLICANT  
Donald Morris, et al.FILING DATE  
May 3, 2001GROUP  
1636OPEN INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

JUL 31 2001 U.S. TRADES & PATENTS OFFICE			
<i>DL</i>	Neto, Y. et al., "Autologous stem-cell transplantation for solid tumors in adults", <i>Hematol. Oncol. Clin. North Am.</i> 13(5):939-968 (1999).		
<i>DL</i>	Norman, K., et al., "Reovirus as a novel oncolytic agent", <i>J. Clin. Invest.</i> 105 (8): 1035-1038 (2000).		
<i>DL</i>	Reichard, K.W., et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", <i>J. of Surgical Research</i> 52:448-453 (1992).		
<i>DL</i>	Stojdl, D.F., et al., "Exploiting Tumor-Specific Defects in the Interferon Pathway with a Previously Unknown Oncolytic Virus", <i>Nat. Med.</i> 6(7):821-825 (2000).		
<i>DL</i>	Romano et al., <i>Mol. and Cell. Bio.</i> 18:7304-7316 (1998).		
<i>DL</i>	Sharp et al., <i>Virol.</i> 250:302-315 (1998).		
<i>DL</i>	Spyridonidis, A. et al., "Minimal residual disease in autologous hematopoietic harvests from breast cancer patients", <i>Annals of Onc.</i> 9:821-826 (1998).		
<i>DL</i>	Steele, T.A., "Recent Developments in the Virus Therapy of Cancer", <i>Proc. Soc. Exp. Biol. Med.</i> 223:118-127 (2000).		
<i>DL</i>	Stewart, D.A., et al., "Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens", <i>Bone Marrow Transplant.</i> 23(2): 111-117 (1999).		
<i>DL</i>	Strong, J.E., et al., "The Molecular Basis of Viral Oncolysis: Usurpation of the Ras Signaling Pathway by Reovirus", <i>EMBO J.</i> 17:3351-3362 (1998).		
<i>DL</i>	Strong, J.E., et al., "Evidence that the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency", <i>Virology</i> 197(1):405-411 (1993).		
<i>DL</i>	Strong, J.E., et al., "The v-erbV oncogene confers enhanced cellular susceptibility to reovirus infection", <i>J. Virol.</i> 70:612-616 (1996).		
<i>DL</i>	Wiman KG , "New p53-Based Anti-Cancer Therapeutic Strategies", <i>Med Oncol.</i> 15(4):222-8 (1998).		
<i>DL</i>	Winter, J.N., "High-dose therapy with stem-cell transplantation in the malignant lymphomas", <i>Onc. (Huntingt)</i> 13(12):1635-1645 (1999).		
<i>DL</i>	Yoon, S.S., et al., "An Oncolytic Herpes Simplex Virus Type I Selectively Destroys Diffuse Liver Metastases from Colon Carcinoma", <i>FASEB J.</i> 14:301-311(2000).		
<i>DL</i>	Zorn, U. et al., "Induction of Cytokines and Cytotoxicity against Tumor Cells by Newcastle Disease Virus", <i>Cancer Biotherapy</i> 9(3):22-235 (1994).		
Examiner Signature	<i>David Lamberton</i>	Date Considered	8/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.